Inverse agonists (antagonism) of CB1R were developed 20 years ago as treatments for obesity: however, rimonabant that did come into use for that purpose was quickly withdrawn because of severe adverse psychiatric effects (Sam et al., 2011). This evidence concerns the gene CNR1 and obesity disorder.